Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opevesostat vs Abiraterone or Enzalutamide in mCRPC (OMAHA-003)
NCT06136624Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2023
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 36
01
Overview
A Phase 3 trial of opevesostat in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Merck & Co.. Started Dec 2023; status: recruiting.
02
Drugs
opevesostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06136624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06136624.